Synopsis:
Brokerages are optimistic about select stocks that have strong growth potential in the second half of the year, projecting 15–20% returns based on robust fundamentals and favorable market trends.
Motilal Oswal and Nuvama Securities recommend strong buy opportunities in the insurance and healthcare sectors for the second half of the year. Motilal Oswal has given a Buy rating to HDFC Life Insurance Ltd and SBI Life Insurance Ltd , while Nuvama has initiated coverage on Max Healthcare Institute Ltd with a Buy rating. Also Emkay Global has given a buy rating to Shree Cement.These picks are backed by solid business fundamentals and positive market outlooks.
HDFC Life Insurance Company Ltd
HDFC Life Insurance Company Ltd is one of India’s leading life insurance providers, offering a wide range of individual and group insurance solutions, including protection, savings, investment-linked, and retirement products. A joint venture between HDFC Ltd and Standard Life (part of Standard Life Aberdeen Group), the company is known for its strong distribution network, digital capabilities, and consistent focus on customer-centric services.
With market capitalization of Rs. 1,66,508 cr, the shares of HDFC Life Insurance Company Ltd are currently trading at Rs. 775.70, from its previous close of Rs. 774.25 per share.
Motilal Oswal has given a Buy rating on HDFC Life Insurance Ltd with a target price of Rs. 910, implying a potential upside of 17% from the current level of Rs. 775.70.
SBI Life Insurance Company Ltd
SBI Life Insurance Company Ltd is one of India’s largest life insurance providers, formed as a joint venture between the State Bank of India (SBI) and BNP Paribas Cardif. The company offers a wide range of life insurance products, including protection plans, savings and investment-linked policies, and retirement solutions, catering to both individual and group customers.
With market capitalization of Rs. 1,81,513 cr, the shares of SBI Life Insurance Company Ltd are currently trading at Rs. 1,817.20 per share, from its previous close of Rs. 1,814.20 per share.
Motilal Oswal has given a Buy rating on SBI Life Insurance Ltd with a target price of Rs. 2,140, implying a potential upside of 18% from the current level of Rs. 1,817.20.
Max Healthcare Institute Ltd
Max Healthcare Institute Ltd is a leading private healthcare provider in India, operating 22 hospitals with over 5,000 beds across major cities. The company offers a wide range of medical services, including oncology, cardiology, orthopedics, and neurology, along with diagnostic services (Max Lab) and home healthcare (Max@Home).
With market capitalization of Rs. 1,14,422 cr, the shares of Max Healthcare Institute Ltd are currently trading at Rs. 1,173.50, from its previous close of Rs. 1,179.30 per share.
Nuvama has initiated coverage on Max Healthcare Institute Ltd with a Buy rating, setting a target price of Rs. 1,430, indicating a potential upside of 22% from the current level of Rs. 1,173.50.
Shree Cement Ltd
Shree Cement Ltd is one of India’s leading cement producers, headquartered in Kolkata, with a total production capacity of 66.8 MTPA across India and overseas. The company manufactures various types of cement under brands like Bangur Cement, Rockstrong, and Roofon, and is expanding its presence in the Ready-Mix Concrete (RMC) segment.
With market capitalization of Rs. 1,07,391 cr, the shares of Shree Cement Ltd are currently trading at Rs. 29,760 per share, from previous close of Rs. 29,830 per share. Emkay Global has given a Buy rating on Shree Cement Ltd with a target price of Rs. 35,300, implying a potential upside of 19% from the current level of Rs. 29,760.
Written by Manideep Appana
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
